APA (7th ed.) Citation

Shrestha, A., Chi, M., Wagner, K., Drake, A., Fulzele, K., Guichard, S., & Malik, P. (2020). Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels. Blood, 136(Supplement 1), 21-22. https://doi.org/10.1182/blood-2020-140875

Chicago Style (17th ed.) Citation

Shrestha, Archana, Mengna Chi, Kimberly Wagner, Adam Drake, Keertik Fulzele, Sylvie Guichard, and Punam Malik. "Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels." Blood 136, no. Supplement 1 (2020): 21-22. https://doi.org/10.1182/blood-2020-140875.

MLA (9th ed.) Citation

Shrestha, Archana, et al. "Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels." Blood, vol. 136, no. Supplement 1, 2020, pp. 21-22, https://doi.org/10.1182/blood-2020-140875.